Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.96 |
| ▸ | NPC1 | O15118 | 7/20 | 0.96 |
| ▸ | MAPT | P10636 | 6/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.96 |
| ▸ | POLB | P06746 | 2/20 | 0.96 |
| ▸ | LTA4H | P09960 | 5/20 | 0.79 |
| ▸ | ATP4A | P20648 | 2/20 | 0.61 |
| ▸ | ATP4B | P51164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127807 | 0.98 | RAB9A (1.00) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| Iodide SCHEMBL5455207 | 0.93 | RAB9A (0.90) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL29654110 | 0.90 | MAPT (0.84) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| Iodide SCHEMBL5461678 | 0.89 | NPC1 (0.82) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1771825 | 0.82 | ALDH1A1 (0.79) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL23610361 | 0.80 | ALDH1A1 (0.83) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL13394699 | 0.80 | MAPT (0.73) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5328219 | 0.80 | ALDH1A1 (0.69) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL28931077 | 0.80 | NPC1 (0.69) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1180215 | 0.80 | MAPT (0.84) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051296-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-02-13 | — | — | US | disclosed |
| US-12103917-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-10-01 | — | — | US | disclosed |
| US-20210300882-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-09-30 | — | — | US | disclosed |
| US-11028061-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-06-08 | — | — | US | disclosed |
| US-20180222874-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Bumham Prebys Medical Discovery Imstitute (US) | 2018-08-09 | — | — | US | disclosed |
| WO-2017019772-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2017-02-02 | — | — | WO | disclosed |
| US-5958910-A | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5877193-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051296-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | MYC, MYCBP, MLYCD | RAB9A 3766/4885NPC1 187/4885MAPT 2121/4885 |
| US-20210300882-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | MYC, MYCBP, MLYCD | RAB9A 3766/4885NPC1 187/4885MAPT 2121/4885 |
| US-20180222874-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | MYC, MYCBP, MLYCD | RAB9A 3766/4885NPC1 187/4885MAPT 2121/4885 |
| US-11028061-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | MYC, MYCBP, MLYCD | RAB9A 3766/4885NPC1 187/4885MAPT 2121/4885 |
| US-12103917-B2 | Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof | MYC, MYCBP, MLYCD | RAB9A 3766/4885NPC1 187/4885MAPT 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.